EW
Edwards Lifesciences Corporation
EW's fundamentals are mixed, but it looks expensive: trading at 60x earnings, above its usual 40x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
EW's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EW PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 28x | $48.93 | -54% |
| Forward | 33x | $106 | — |
| Fair | 39x | $69.87 | -34% |
| Expensive | 57x | $102 | -3.9% |
| Current | 60x | $106 | — |
Historical ranges are pointers, not guarantees.
EW's PE is in its expensive range at 60x. If earnings grow as analysts expect, today's price would be 33x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EW Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
EW has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.25 | +84% |
| Q3 2026 | $1.77 | -24% |
| Q2 2026 | $1.74 | -75% |
| Q1 2026 | $1.88 | -73% |
| Q4 2025 | $1.83 | -74% |
| Q3 2025 | $2.32 | -67% |
| Q2 2025 | $6.95 | +186% |
| Q1 2025 | $7.00 | +202% |
| Q4 2024 | $6.97 | +203% |
EW has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7B | +10% |
| Q2 2026 | $1.7B | +14% |
| Q1 2026 | $1.6B | +17% |
| Q4 2025 | $1.6B | +13% |
| Q3 2025 | $1.6B | +15% |
| Q2 2025 | $1.5B | +11% |
| Q1 2025 | $1.4B | -12% |
| Q4 2024 | $1.4B | -9.7% |
EW's revenue has grown year over year for six quarters in a row: $1.7B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | -2.3 points |
| Q2 2026 | 29% | +2.6 points |
| Q1 2026 | 29% | +1 points |
| Q4 2025 | 9.6% | -13 points |
| Q3 2025 | 20% | -6.1 points |
| Q2 2025 | 27% | +0.2 points |
| Q1 2025 | 28% | +3.7 points |
| Q4 2024 | 23% | -3.5 points |
EW has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over EW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
EW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $506.7M | -1.8% |
| Q2 2026 | $585M | +143% |
| Q1 2026 | -$21.1M | -109% |
| Q4 2025 | $353.5M | +$530.8M |
| Q3 2025 | $516.2M | +72% |
| Q2 2025 | $240.9M | -16% |
| Q1 2025 | $224.4M | +$343.2M |
| Q4 2024 | -$177.3M | -467% |
EW generated $1.4B in free cash flow over the past year, up 77% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over EW on cash flow, with more consistent year-over-year improvement.
EW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -1.4% | -8.1M shares |
| 3 years | -5.2% | -31.9M shares |
| 5 years | -8.6% | -54.1M shares |
| Available history | -9.3% | -59M shares |
EW has 578M diluted shares, down 1.4% from a year ago, with $755M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $138.9M |
| Q2 2026 | $153.3M |
| Q1 2026 | $421.8M |
| Q4 2025 | $40.6M |
| Q3 2025 | $588.7M |
| Q2 2025 | $5.5M |
| Q1 2025 | $258.6M |
| Q4 2024 | $100.1M |
EW spent $755M buying back its own shares over the past year, down 21% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.6x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -1.7x | Net Cash |
| Q3 2025 | -1.3x | Net Cash |
| Q2 2025 | -1.7x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
EW has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
EW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.7 | Overbought |
| Stochastic | 87.7 | Overbought |
EW's weekly RSI is 72 (overbought) and its Stochastic is 88 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EW PE vs Healthcare Sector
| Metric | EW | Sector median | Relative |
|---|---|---|---|
| PE | 60x | 26x | 131% above |
| PE % | 84 | 29 | 55 pts above |
EW is trading at 60x earnings, a 131% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $91.5 | 16% above |
| 20 week MA | $89.9 | 18% above |
| 50 week MA | $85.9 | 23% above |
| 100 week MA | $80.9 | 31% above |
| 200 week MA | $80.0 | 32% above |
EW has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.2 | $88.6 | +13% |
| 2021 | $88.6 | $128.6 | +45% |
| 2022 | $128.6 | $74.2 | -42% |
| 2023 | $74.2 | $76.3 | +2.8% |
| 2024 | $76.3 | $75.7 | -0.8% |
| 2025 | $75.7 | $86.9 | +15% |
| 2026 YTD | $86.9 | $105.8 | +22% |
EW has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.